Quibim

Executive Summary

Quibim is a Spanish medical imaging AI company founded in 2012 that specializes in extracting quantitative biomarkers from medical images using radiomics and deep learning. Its cloud-based platform transforms imaging data into actionable predictions for precision medicine, serving both life sciences companies and healthcare providers. The company focuses on oncology, neurology, and metabolic diseases through its suite of software-as-a-medical-device (SaMD) products and analytics services. By enabling scalable, objective analysis of imaging data, Quibim positions itself as a key enabler of precision diagnostics and drug development. With regulatory clearances in Europe and ongoing clinical validations, the company has established credibility in the AI diagnostics space. Its technology is designed to integrate seamlessly into clinical workflows, supporting earlier detection and better treatment monitoring. As the demand for AI-powered biomarkers grows, Quibim is well-placed to expand its commercial footprint and capture market share in both the pharmaceutical and healthcare provider segments. The company’s focus on quantitative, reproducible biomarkers aligns with the broader shift toward data-driven precision medicine, offering significant potential for adoption and revenue growth.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance for a new oncology imaging biomarker product70% success
• Q3 2025Strategic partnership with a major pharmaceutical company for AI-powered imaging in clinical trials65% success
• Q4 2025Series C funding round to accelerate commercialization80% success